Caplyta vs Adderall
A side-by-side look at two mental health medications advertised on TV. Informational only — not medical advice.
| US Caplyta | US Adderall | |
|---|---|---|
| Generic name | lumateperone | amphetamine/dextroamphetamine |
| Drug class | Atypical Antipsychotic | CNS Stimulant |
| Treats | Schizophrenia, bipolar depression | ADHD, narcolepsy |
| Category | Mental Health | Mental Health |
| Manufacturer | Intra-Cellular Therapies | Teva |
| Year approved | 2019 | 1996 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $130M | $1M |
| Common side effects | Drowsiness, Dry mouth, Dizziness, Nausea | High potential for abuse and dependence, Insomnia, Decreased appetite, Increased heart rate |
Frequently asked questions
Is Caplyta or Adderall better?
Neither is universally "better." Caplyta (lumateperone) and Adderall (amphetamine/dextroamphetamine) are both used for mental health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Caplyta and Adderall?
Caplyta is a Atypical Antipsychotic made by Intra-Cellular Therapies, while Adderall is a CNS Stimulant made by Teva. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Caplyta has the larger estimated TV advertising budget of the two.